An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Eteplirsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Registrational
- Sponsors Sarepta Therapeutics
- 14 Nov 2017 Planned End Date changed from 1 Feb 2018 to 1 Jan 2019.
- 14 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2019.
- 31 May 2017 Status changed from recruiting to active, no longer recruiting.